Durable responses in aRCC, how do we optimise treatment?

Share :
Published: 29 Jul 2024
Views: 2257
Rating:
Save
Prof Roberto Iacovelli and Prof Viktor Grünwald

Case study of a patient with deep response
First-line choices for aRCC
Best treatment combination for poor-risk patients and how they perform?
The best therapeutical approach in the long term, after 18-24 months of therapy, considering the impact on QoL of manageable but bothersome AE
What to do with a patient who had not had a prior nephrectomy or evidence of metastatic disease but lesions remain in the kidneys
What to expect and aim for?

 

This non-promotional, educational event has been organized and funded by Eisai Europe LTD., it is intended for Health Care Professionals only. This material is not intended for UK HCPs. Eisai products will be discussed.